Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trientine for hypertrophic cardiomyopathy
ISRCTN57145331Phase 2Completed
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Trientine with Placebo (2 arms). Primary endpoint: Change in left ventricular mass index. Started Mar 2021; status: completed.
02
Drugs
trientine
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on ISRCTN57145331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN57145331.